FDA warns of rare vision-loss side effect from GLP-1 drugs
The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with GLP-1 drugs like Ozempic, Wegovy and other brands.
Watch CBS News
The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with GLP-1 drugs like Ozempic, Wegovy and other brands.
Illinois Gov. JB Pritzker said he has lost 80 pounds since he started taking a GLP-1 drug. Dr. Christopher Chapman of Rush University Medical Center joins Marie Saavedra with a breakdown on GLP-1 drugs, their benefits, and their side effects.
As obesity rates among Americans drop and weight loss drugs lead to a slimmer society, airlines could save on fuel costs, according to a recent analysis.
The Food and Drug Administration has approved Wegovy in pill form. Dr. Jon LaPook has the story of one man, Dr. Chris Mertens, who saw results.
Bennett, a former carb addict, gives insight into why she says 21 days is the key to dieting success.
Health journalist Connie Bennett shares proven ways to help lose those pounds, including a 21-day plan, focusing on mindset, and recognizing the challenges that can get you off track.
WeightWatchers, founded in 1963, has struggled to shed debt and cope with the emergence of weight loss drugs.
The ad from the telehealth company Hims & Hers promoted the company’s compounded weight loss drugs. The ad portrayed the obesity epidemic as a rigged game because of the greedy health care system. Dr. Justin Ryder, who studies child obesity and treatment at Northwestern Medicine, has some perspective.
The demand for weight loss drugs like Ozempic and Wegovy is sky high, and some are asking about safe alternatives. But do these products work? University of Illinois Professor Dr. Patrick Sweeney joins us to talk about it.
Drugs like Ozempic and Wegovy have been booming in recent years as people use them for weight loss, but their popularity is making it harder to get them, and some are instead turning to off-brand versions.
